Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 4472-2 (MIR4472-2) is a short, non-coding RNA molecule involved in post-transcriptional regulation of gene expression. MIR4472-2 is upregulated in highly metastatic breast cancer, where it promotes tumor growth, invasiveness, and chemoresistance by downregulating genes such as RGMA (Repulsive Guidance Molecule A), which acts as a tumor suppressor. By targeting RGMA and inducing epithelial-to-mesenchymal transition (EMT), MIR4472-2 contributes to cancer cell migration and metastasis. As a microRNA, its main mode of action is incorporation into the RNA-induced silencing complex (RISC), guiding the complex to complementary target mRNAs to suppress their expression. Its expression profile and functional roles nominate MIR4472-2 as both a possible biomarker and a candidate therapeutic target in oncology, although further research is needed for clinical applications.
Post-transcriptional gene silencing by targeting mRNA, leading to its degradation or translational inhibition
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 4472-2 (MIR4472-2).